Results 111 to 120 of about 52,877 (267)

Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

open access: yes, 2020
Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies.
Ahmed Elgazzar   +5 more
semanticscholar   +1 more source

Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance

open access: yesnew microbes and new infections, 2020
Alarming situation has been caused due to the emergence of COVID-19 infection around the world. There is an urgency of developing a therapeutic strategy in order to control the spread of COVID-19.
Renuka Choudhary, A. Sharma
semanticscholar   +1 more source

Allergen immunotherapy for equine insect bite hypersensitivity: Does it reduce clinical signs?

open access: yesEquine Veterinary Education, EarlyView.
Summary Insect bite hypersensitivity (IBH) is a common, recurrent allergic skin disease of horses. This critically appraised topic evaluated whether therapeutic allergen immunotherapy (AIT) reduces clinical signs in affected horses. Four databases were searched and five therapeutic clinical studies were retained.
R. Cao, E. Maina
wiley   +1 more source

Epigenetic control of cellular plasticity in breast cancer progression

open access: yesThe FEBS Journal, EarlyView.
Cancer cells undergo cell state transitions, termed plasticity, driving cancer progression and dictating therapeutic response. We define breast cancer plasticity into four interconnected processes: (1) breast cancer stem cell fates, (2) epithelial‐to‐mesenchymal transition, (3) maintenance of luminal identity, and (4) acquisition of therapeutic ...
Ellie J. Massey   +2 more
wiley   +1 more source

Evaluation of in vitro drug-drug interactions of ivermectin and antimalarial compounds

open access: yesMalaria Journal
Background Ivermectin is lethal to Anopheles mosquitoes and a novel approach to malaria transmission control. Ivermectin could be co-administered with antimalarial drugs in mass drug administration, seasonal malaria chemoprevention, or other ...
Phornpimon Tipthara   +3 more
doaj   +1 more source

Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2007
BACKGROUND: Onchocerca volvulus is the causative agent of onchocerciasis, or "river blindness". Ivermectin has been used for mass treatment of onchocerciasis for up to 18 years, and recently there have been reports of poor parasitological responses to ...
Catherine Bourguinat   +6 more
doaj   +1 more source

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

open access: yes, 2020
The broad-spectrum antiparasitic agent ivermectin has been very recently found to inhibit SARS-CoV-2 in vitro and proposed as a candidate for drug repurposing in COVID-19. In the present report the in vitro antiviral activity end-points are analyzed from
G. Momekov, D. Momekova
semanticscholar   +1 more source

Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial

open access: yes, 2021
Introduction: The rate of secondary attacks of SARS-COV-2 is high among household close contacts Social distancing, isolation and infection control measures are important for preventing exposure to infection, but insufficient Aim: The study aimed to ...
Waheed M Shoumann   +7 more
semanticscholar   +1 more source

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley   +15 more
wiley   +1 more source

Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis.

open access: yesPLoS Neglected Tropical Diseases, 2013
BackgroundRecent studies in Mali, Nigeria, and Senegal have indicated that annual (or biannual) ivermectin distribution may lead to local elimination of human onchocerciasis in certain African foci.
Hugo C Turner   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy